KAVL has had a strong fall down to a long-term demand zone. High risk play but big bounce potential.
Note
$400m before the FDA shenanigans. 
40M expected afterwards.Price drop from $5 to $0.50.
FDA shenanigans reversed.
$5 inc
Note
BoomNote
Bout time for another bounce. Hard floor at 10 cents.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.